Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This was a single-dose, randomized, double-blind, placebo-controlled, 3 way crossover study
designed to evaluate the relative abuse potential of crushed EMBEDA® compared to morphine
sulfate CR tablets and placebo in healthy male and female, non-dependent, recreational opioid
users. An appropriate dose of morphine sulfate CR (i.e., 30 mg, 60 or 90 mg) was to be
selected during Part A of the study (Dose Selection Phase). Each subject participated in the
study for up to (approximately) 16 weeks and was confined in the clinic for a total of up to
12 nights.